Dr. Nicolas Loebel, Sinuwave President and Chief Technology Officer
Dr. Loebel will be introducing to the European photobiology community pre-clinical and clinical results in a presentation entitled, 'Clinical application of antimicrobial photodynamic therapy to chronic disease states'.
Bothell, Washington (PRWEB) September 05, 2013
Sinuwave Technologies Corporation is pleased to announce that Dr. Nicolas Loebel, its President and Chief Technology Officer, is presenting at the 15th Congress of the European Society for Photobiology. The 2013 Congress is being held in Liège (Belgium) from September 2- 6, 2013.
The European Society of Photobiology Congress meetings are generally accepted as one of the leading global conferences in the field of Photobiology. In addition to congregating the leaders in the field of Photomedicine, Photobiology and Photodynamic Therapy, these meetings are important forums for dissemination of advanced knowledge and technological development in most photobiological fields of research, for scientific discussions and exchange of new ideas, and for establishing new collaborations for future research.
Dr. Loebel will be introducing to the European photobiology community pre-clinical and clinical results in a presentation entitled, “Clinical application of antimicrobial photodynamic therapy to chronic disease states”. Sinuwave is a treatment for chronic sinusitis patients based on Photodisinfection that is currently available in Canada.
Photodisinfection is an important new technology for chronic sinusitis as it has unique dual action capabilities of instantly eliminating harmful biofilm infections (along with their virulence factors) as well as addressing the chronic inflammation caused by these pathogens. Specifically, Photodisinfection is highly effective at eradicating Staphylococcus aureus and Pseudomonas aeruginosa - two of the most common super antigen producing pathogens associated with chronic refractory sinusitis.
Sinuwave Technologies Corporation is the global leader in developing Photodisinfection based therapies for the Sinusitis market. Sinusitis is a common disease affecting approximately 14% of the population. Chronic sinusitis, a more severe and recurring form of the disease, affects about one quarter of this group, or about 4% of the total population. It is estimated that there are over 500,000 patients in the United States alone who suffer from refractory chronic sinusitis, for which there are currently no known solutions. For more information, please visit http://www.sinuwave.com.
